Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

Breast cancer (BC) is the most common malignancy worldwide among women [1]. While earlier detection and improved treatments have contributed to BC mortality decline since the 1990s [2], it remains the leading cause of mortality among women, causing 685,000 deaths globally in 2020 [1]. The 2018 American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines categorize BC as hormone receptor-positive (HR+; tumors with> 10% of cells staining positive for estrogen receptors [ERs] and/or progesterone receptors [PRs] by immunohistochemistry [IHC]; 1 –10% cell staining is considered “low positive”) or HR-negative (HR–; tumors with

Source: Cancer Treatment Reviews - December 8, 2023 Category: Cancer & Oncology Authors: Komal Jhaveri, Frederik Marm é Tags: Tumour Review Source Type: research